Zeptide Insulin Cartridge Blend Suspension
NDC Package 87994-011-97

11-digit billing NDC: 87994001197
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Zeptide Insulin Cartridge Blend suspension is a drug for further processing. This formulation utilizes a suspension delivery system. Marketed by Tirzepatide Pharma, this product is identified by NDC 87994-011.

Identification & Billing

NDC Package Code
87994-011-97
Package Description
2500 SUSPENSION in 1 CARTRIDGE
Product Code
87994-011
11-Digit Billing Format
87994001197

Clinical Specifications

Proprietary Name
Zeptide Insulin Cartridge Blend
Non-Proprietary Name
Zeptide Insulin Cartridge Blend
Substance Name
Insulin Aspart; Isophane Insulin Human Suspension
Dosage Form
Suspension - A liquid1 dosage form that contains solid particles dispersed in a liquid vehicle.
Active Ingredient(s)

Regulatory & Marketing

Labeler Name
Tirzepatide Pharma
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
09-01-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 87994-011-97 identifies a specific commercial package of 2500 suspension in 1 cartridge of Zeptide Insulin Cartridge Blend (UNFINISHED drug), drug for further processing labeled by Tirzepatide Pharma. This suspension is formulated for use and contains insulin aspart; isophane insulin human suspension as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Tirzepatide Pharma on September 01, 2026. The current certification is valid through December 31, 2027.

How is this Tirzepatide Pharma product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 87994001197. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
87994-011-97
11-Digit CMS (5-4-2)
87994-0011-97

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.